Reduction in Disease Progression by Inhibition of Transforming Growth Factor a–CCL2 Signaling in Experimental Posttraumatic Osteoarthritis

Arthritis and Rheumatology

Volumn 67, Issue 10, 2015, Pages 2691-2701

  Appleton, C Thomas G ^a   Usmani, Shirine E ^a   Pest, Michael A ^a   Pitelka, Vasek ^a   Mort, John S ^b   Beier, Frank ^a  

^a WESTERN UNIVERSITY   (Canada)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; BENZOXAZINE DERIVATIVE; CCL2 PROTEIN, RAT; MONOCYTE CHEMOTACTIC PROTEIN 1; QUINAZOLINE DERIVATIVE; RS 504393; SPIRO COMPOUND; TRANSFORMING GROWTH FACTOR ALPHA; TYRPHOSTIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; ARTICULAR CARTILAGE; COMPLICATION; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; INJURY; MALE; OSTEOARTHRITIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; UPREGULATION;

ANIMALS; BENZOXAZINES; CARTILAGE, ARTICULAR; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; MALE; OSTEOARTHRITIS; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SPIRO COMPOUNDS; TRANSFORMING GROWTH FACTOR ALPHA; TYRPHOSTINS; UP-REGULATION; WOUNDS AND INJURIES;

EID: 84958074257     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/ART.39255     Document Type: Article

References (47)

1. Kopec JA, Rahman MM, Berthelot JM, Le Petit C, Aghajanian J, Sayre EC, et al. Descriptive epidemiology of osteoarthritis in British Columbia, Canada. J Rheumatol 2007;34:386–93.
2. Green GA. Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone 2001;3:50–60.
3. Brown TD, Johnston RC, Saltzma CL, Marsh JL, Buckwalter JA. Posttraumatic osteoarthritis: a first estimate of incidence, preva-lence, and burden of disease. J Orthop Trauma 2006;20:739–44.
4. Hunter DJ, Pike MC, Jonas BL, Kissin E, Krop J, McAlindon T. Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet Disord 2010;11:232.
5. Hellio le Graverand MP, Clemmer RS, Redifer P, Brunell RM, Hayes CW, Brandt KD, et al. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis 2013;72:187–95.
6. Reginster JY, Badurski J, Bellamy N, Bensen W, Chapurlat R, Chevalier X, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, rando-mised placebo-controlled trial. Ann Rheum Dis 2013;72:179–86.
7. Cho TJ, Lehmann W, Edgar C, Sadeghi C, Hou A, Einhorn TA, et al. Tumor necrosis factor a activation of the apoptotic cascade in murine articular chondrocytes is associated with the induction of metalloproteinases and specific pro-resorptive factors. Arthritis Rheum 2003;48:2845–54.
8. Martin JA, Brown T, Heiner A, Buckwalter JA. Post-traumatic osteoarthritis: the role of accelerated chondrocyte senescence. Biorheology 2004;41:479–91.
9. Appleton CT, Usmani SE, Bernier SM, Aigner T, Beier F. Transforming growth factor a suppression of articular chondro-cyte phenotype and Sox9 expression in a rat model of osteoar-thritis. Arthritis Rheum 2007;56:3693–705.
10. Bell DM, Leung KK, Wheatley SC, Ng LJ, Zhou S, Ling KW, et al. SOX9 directly regulates the type-II collagen gene. Nat Genet 1997;16:174–8.
11. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by colla-genases in osteoarthritic articular cartilage. J Clin Invest 1997;99: 1534–45.
12. Pickvance EA, Oegema TR, Thompson RC. Immunolocalization of selected cytokines and proteases in canine articular cartilage after transarticular loading. J Orthop Res 1993;11:313–23.
13. Appleton CT, McErlain DD, Pitelka V, Schwartz N, Bernier SM, Henry JL, et al. Forced mobilization accelerates pathogene-sis: characterization of a preclinical surgical model of osteoar-thritis. Arthritis Res Ther 2007;9:R13.
14. Appleton CT, Pitelka V, Henry J, Beier F. Global analyses of gene expression in early experimental osteoarthritis. Arthritis Rheum 2007;56:1854–68.
15. Hallbeck AL, Walz TM, Briheim K, Wasteson A. TGF-a and ErbB2 production in synovial joint tissue: increased expression in arthritic joints. Scand J Rheumatol 2005;34:204–11.
16. Appleton CT, Usmani SE, Mort JS, Beier F. Rho/ROCK and MEK/ERK activation by transforming growth factor-a induces articular cartilage degradation. Lab Invest 2010;90:20–30.
17. Usmani SE, Appleton CT, Beier F. Transforming growth factor-a induces endothelin receptor A expression in osteoarthritis. J Orthop Res 2012;30:1391–7.
18. Zhang YW, Su Y, Lanning N, Swiatek PJ, Bronson RT, Sigler R, et al. Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. Proc Natl Acad Sci U S A 2005;102:11740–5.
19. Zhu J, Jia X, Xiao G, Kang Y, Partridge NC, Qin L. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem 2007;282:26656–64.
20. Yuan GH, Masuko-Hongo K, Sakata M, Tsuruha JI, Onuma H, Nakamura H, et al. The role of C-C chemokines and their receptors in osteoarthritis. Arthritis Rheum 2001;44:1056–70.
21. Harris Q, Seto J, O’Brien K, Lee PS, Kondo C, Heard BJ, et al. Monocyte chemotactic protein-1 inhibits chondrogenesis of syno-vial mesenchymal progenitor cells: an in vitro study. Stem Cells 2013;31:2253–65.
22. Pavlidis P, Qin J, Arango V, Mann JJ, Sibille E. Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex. Neu-rochem Res 2004;29:1213–22.
23. Sztrolovics R, Alini M, Roughley PJ, Mort JS. Aggrecan degradation in human intervertebral disc and articular cartilage. Biochem J 1997;326:235–41.
24. Seguin CA, Bernier SM. TNFa suppresses link protein and type II collagen expression in chondrocytes: role of MEK1/2 and NF-kB signaling pathways. J Cell Physiol 2003;197:356–69.
25. Pritzker KP, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 2006;14:13–29.
26. Gong JH, Nicholls EF, Elliott MR, Brown KL, Hokamp K, Roche FM, et al. G-protein-coupled receptor independent, immunomodulatory properties of chemokine CXCL9. Cell Immunol 2010;261:105–13.
27. Ellis AG, Doherty MM, Walker F, Weinstock J, Nerrie M, Vitali A, et al. Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem Pharmacol 2006;71:1422–34.
28. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995;267:1782–8.
29. Osherov N, Levitzki A. Epidermal-growth-factor-dependent activation of the src-family kinases. Eur J Biochem 1994;225:1047–52.
30. Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, et al. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J Biol Chem 2000;275:25562–71.
31. Louboutin H, Debarge R, Richou J, Selmi TA, Donell ST, Neyret P, et al. Osteoarthritis in patients with anterior cruciate ligament rupture: a review of risk factors. Knee 2009;16:239–14.
32. Goodman SB, Lee J, Smith RL, Csongradi JC, Fornasier VL. Mechanical overload of a single compartment induces early degenerative changes in the rabbit knee: a preliminary study. J Invest Surg 1991;4:161–70.
33. Poole AR, Ionescu M, Swan A, Dieppe PA. Changes in cartilage metabolism in arthritis are reflected by altered serum and syno-vial fluid levels of the cartilage proteoglycan aggrecan: implications for pathogenesis. J Clin Invest 1994;94:25–33.
34. Kammermann JR, Kincaid SA, Rumph PF, Baird DK, Visco DM. Tumor necrosis factor-a (TNF-a) in canine osteoarthritis: immuno-localization of TNF-a, stromelysinandTNFreceptorsincanine osteoarthritic cartilage. Osteoarthritis Cartilage 1996;4:23–34.
35. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 2001;44:555–94.
36. Burleigh A, Chanalaris A, Gardiner MD, Driscoll C, Boruc O, Saklatvala J, et al. Joint immobilization prevents murine osteoar-thritis and reveals the highly mechanosensitive nature of prote-ase expression in vivo. Arthritis Rheum 2012;64:2278–88.
37. Zhang X, Xhu J, Liu F, Li Y, Chandra A, Levin LS, et al. Reduced EGFR signaling enhances cartilage destruction in a mouse osteoarthritis model. Bone Res 2013;2:14715.
38. Shepard JB, Jeong JW, Maihle NJ, O’Brien S, Dealy CN. Tran-sient anabolic effects accompany epidermal growth factor receptor signal activation in articular cartilage in vivo. Arthritis Res Ther 2013;15:R60.
39. Staal B, Williams BO, Beier F, Vande Woude GF, Zhang YW. Cartilage-specific deletion of Mig-6 results in osteoarthritis-like disorder with excessive articular chondrocyte proliferation. Proc Natl Acad Sci U S A 2013;111:9590–5.
40. Pest MA, Russell BA, Zhang YW, Jeong JW, Beier F. Dis-turbed cartilage and joint homeostasis resulting from a loss of mitogen-inducible gene 6 in a mouse model of joint dysfunction. Arthritis Rheumatol 2014;66:2816–27.
41. Miller RE, Tran PB, Das R, Ghoreishi-Haack N, Ren D, Miller RJ, et al. CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. Proc Natl Acad Sci U S A 2012;109:20602–7.
42. Echtermeyer F, Bertrand J, Dreier R, Meinecke I, Neugebauer K, Fuerst M, et al. Syndecan-4 regulates ADAMTS-2 activation and cartilage breakdown in osteoarthritis. Nat Med 2009;15: 1072–6.
43. Lin AC, Seeto BL, Bartoszko JM, Khoury MA, Whetstone H, Ho L, et al. Modulating hedgehog signaling can attenuate the severity of osteoarthritis. Nat Med 2009;15:1421–5.
44. Saito T, Fukai A, Mabuchi A, Ikeda T, Yano F, Ohba S, et al. Tran-scriptional regulation of endochondral ossification by HIF-2a during skeletal growth and osteoarthritis development. Nat Med 2010;16: 648–86.
45. Sampson ER, Hilton MJ, Tian Y, Chen D, Schwarz EM, Mooney RA, et al. Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis. Sci Transl Med 2011;3:101ra93.
46. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, Larsen DM, et al. Identification of a central role for complement in osteoarthritis. Nat Med 2011;17:1674–6.
47. Yang S, Kim J, Ryu JH, Oh H, Chun CH, Kim BJ, et al. Hypoxia-inducible factor-2a is a catabolic regulator of osteoarthritic cartilage destruction. Nat Med 2010;16:687–93.